enGene Therapeutics Inc. (ENGN) — Operating Cash Flow

Annual figures by fiscal year, from SEC filings.

2022: -$17.59M2023: -$24.74M2024: -$48.28M2025: -$99.24M-$99.24M
2022Operating Cash Flow (USD)2025
Fiscal YearOperating Cash FlowChange YoY
2025-$99.24M-105.5%
2024-$48.28M-95.1%
2023-$24.74M-40.6%
2022-$17.59M